COMP <GO>
COCP vs AKTX // EV/EBITDA & P/E VALUATION
Cocrystal Pharma Inc. (NASDAQ) VS. Akari Therapeutics plc ADS (NASDAQ) • 15-METRIC TALLY: COCP 2
— AKTX 1
■ METRIC PARITY
LAST: $0.98 (-1.01%) • MKT CAP: $18.9M
valuation
—
LAST: $8.00 (-13.04%) • MKT CAP: $18.3M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (COCP VS. AKTX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | COCP | AKTX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 2/9 | +1.00 | COCP | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 44.5 | 47.0 | -2.45 | AKTX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $18.9M | $18.3M | $596.6K | COCP | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | COCP REV | AKTX REV | COCP GROSS % | AKTX GROSS % | COCP FCF | AKTX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $0 | — | — | -$8.2M | -$10.6M |
| FY 2024 | $0 | $0 | — | — | -$16.5M | -$12.6M |
| FY 2023 | $0 | $367.9K | — | — | -$14.7M | -$16.4M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
COCP // BETA —
AKTX // BETA —